Advancing Cancer Treatment with Brilliant Chemistry:
‍Learn About Zentalis' Clinical-Stage Oncology Therapies

Known cancer biology.
Deliberate medicinal chemistry.
Improving patient lives.

About Zentalis

Improving Patient lives

We are a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers.

Learn More

News

Read more

Pipeline

Compound
Indication
Trial Name + Development Approach
Phase 1
Phase 2
Phase 3

Azenosertib Being Studied As Monotherapy And Combination In Multiple Tumors

Studies for Lead Indication
Other Studies Ongoing
PROC
Monotherapy
DENALI Part 1b
Phase 2
PROC
Monotherapy
DENALI Part 2
Registration-intent
Cyclin E1+
FDA Fast Track Designation
Phase 2
PROC
Monotherapy
Randomized Confirmatory Study
Azenosertib vs. SOC chemo
Cyclin E1+
Phase 3
Uterine Serous Carcinoma
Monotherapy
TETON (ZN-c3-004)
FDA Fast Track Designation
Phase 2
Ovarian Cancer
Combination
ZN-c3-002
Azenosertib + multiple chemo backbones and bevacizumab
Phase 1
BRAF Mutant Colorectal cancer
Combination
ZN-c3-016
Azenosertib + encorafenib and cetuximab
Phase 1

Ongoing Study

Planned Study

Learn More

Join Zentalis

Be part of our vibrant team of dedicated professionals with the common goal of helping cancer patients and make a lasting impact.

Explore Careers